Molecular and genetic bases of neuroblastoma

International Journal of Clinical Oncology

Volumn 17, Issue 3, 2012, Pages 190-195

  Kamijo, Takehiko ^a   Nakagawara, Akira ^a  

^a CHIBA CANCER CENTER   (Japan)

Author keywords

Molecular and genetic abnormality; Neuroblastoma

Indexed keywords

ANTINEOPLASTIC AGENT; CD133 ANTIGEN; DECA 14; GENOMIC DNA; POLO LIKE KINASE 1; POLO LIKE KINASE 1 INHIBITOR; PROTEIN KINASE INHIBITOR; RAPAMYCIN; UNCLASSIFIED DRUG;

ALK GENE; ALLELE; ANTINEOPLASTIC ACTIVITY; BMI1 GENE; CANCER CLASSIFICATION; CANCER GENETICS; CANCER PROGNOSIS; CANCER STEM CELL; CANCER SURVIVAL; CARCINOGENESIS; CHROMOSOME 11Q; CHROMOSOME 17Q; CHROMOSOME 1P; CHROMOSOME LOSS; CLINICAL FEATURE; COPY NUMBER VARIATION; FAMILIAL CANCER; GENE AMPLIFICATION; GENE LOSS; GENETIC ASSOCIATION; GENETIC GAIN; GENETIC HETEROGENEITY; HISTOPATHOLOGY; HUMAN; METASTASIS; MOLECULAR GENETICS; MOLECULARLY TARGETED THERAPY; MYCN GENE; NEUROBLASTOMA; NONHUMAN; NUCLEOTIDE SEQUENCE; ONCOGENE; PHOX2B GENE; PLOIDY; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SURVIVAL TIME;

CHILD; DNA; HUMANS; NEOPLASTIC STEM CELLS; NEUROBLASTOMA; NUCLEAR PROTEINS; ONCOGENE PROTEINS; PLOIDIES;

EID: 84862902806     PISSN: 13419625     EISSN: 14377772     Source Type: Journal    
DOI: 10.1007/s10147-012-0415-7     Document Type: Review

References (58)

1. Westermann F, Schwab M (2002) Genetic parameters of neu-roblastomas. Cancer Lett 184:127-147
2. Maris JM, Hogarty MD, Bagatell R et al (2007) Neuroblastoma. Lancet 369:2106-2120
3. van Noesela MM, Versteeg R (2004) Pediatric neuroblastomas: genetic and epigenetic 'danse macabre'. Gene 325:1-15
4. D'Angio GJ, Evans AE, Koop CE (1971) Special pattern of widespread neuroblastoma with a favourable prognosis. Lancet 297:1046-1049
5. Kato GJ, Lee WM, Chen LL et al (1992) Max: functional domains and interaction with c-Myc. Genes Dev 6:81-92
6. Zindy F, Eischen CM, Randle DH et al (1998) Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization. Genes Dev 12:2424-2433
7. Kohl NE, Kanda N, Schreck RR et al (1983) Transposition and amplification of oncogene related sequence in human neurobl-astomas. Cell 35:359-367
8. Schwab M, Alitalo K, Klempnauer KH et al (1983) Amplified DNA with limited homology to myc cellular oncogene is shared by human neuroblastoma cell lines and a neuroblastoma tumor. Nature 305:245-248
9. Corvi R, Amler LC, Savelyeva L et al (1994) MYCN is retained in single copy at chromosome 2 band p23-24 during amplification in human neuroblastoma cells. Proc Natl Acad Sci USA 91:5523-5527
10. Schwab M (1998) Amplification of oncogenes in human cancer cells. Bioessays 20:473-479
11. Seeger RC, Brodeur GM, Sather H et al (1985) Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N Engl J Med 313:1111-1116
12. Brodeur G, Seeger RC, Schwab M et al (1984) Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science 224:1121-1124
13. Rubie H, Hartmann O, Michon J et al (1997) Localized neuro-blastoma: MYCN amplification is the main prognostic factor-results of the NBL 90 study. J Clin Oncol 15:1171-1182
14. Caron H (1995) Allelic loss of chromosome 1 and additional chromosome 17 material are both unfavourable prognostic markers in neuroblastoma. Med Pediatr Oncol 24:215-221
15. Bown N, Cotterill S, Lastowska M et al (1999) Gain of chromosome arm 17q and adverse outcome in patients with neuro-blastoma. N Engl J Med 340:1954-1961
16. Okabe-Kado J, Kasukabe T, Honma Y et al (2005) Clinical significance of serum NM23-H1 protein in neuroblastoma. Cancer Sci 96:653-660
17. Adida C, Berrebi D, Peuchmaur M et al (1998) Anti-apoptosis gene, survivin, and prognosis of neuroblastoma. Lancet 351:882-883
18. White PS, Maris JM, Beltinger C et al (1995) A region of consistent deletion in neuroblastoma maps within 1p36.2-3. Proc Natl Acad Sci USA 92:5520-5524
19. Caron H, Spieker N, Godfried M et al (2001) Chromosome bands 1p35-36 contain two distinct neuroblastoma tumor suppressor loci, one of which is imprinted. Genes Chromosom Cancer 30:168-174
20. Bauer A, Savelyeva L, Claas A et al (2001) Smallest region of overlapping deletion in 1p36 in human neuroblastoma: a 1 Mbp cosmid and PAC contig. Genes Chromosom Cancer 31:228-239
21. Brodeur GM (2003) Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer 3:203-216
22. Wei JS, Song YK, Durinck S et al (2008) The MYCN oncogene is a direct target of miR-34a. Oncogene 27:5204-5213
23. Cole KA, Attiyeh EF, Mosse YP et al (2008) A functional screen identifies miR-34a as a candidate neuroblastoma tumor suppressor gene. Mol Cancer Res 6:735-742
24. Bagchi A, Papazoglu C, Wu Y et al (2007) CHD5 is a tumor suppressor at human 1p36. Cell 128:459-475
25. Munirajan AK, Ando K, Mukai A et al (2008) KIF1Bbeta functions as a haploinsufficient tumor suppressor gene mapped to chromosome 1p36.2 by inducing apoptotic cell death. J Biol Chem 283:24426-24434
26. Guo C, White PS, Weiss MJ et al (1999) Allelic deletion at 11q23 is common in MYCN single copy neuroblastomas. Oncogene 18:4948-4957
27. Spitz R, Hero B, Ernestus K et al (2003) Deletions in chromosome arms 3p and 11q are new prognostic markers in localized and 4s neuroblastoma. Clin Cancer Res 9:52-58
28. Attiyeh EF, London WB, Mosse YP et al (2005) Chromosome 1p and 11q deletions and outcome in neuroblastoma. N Engl J Med 353:2243-2253
29. Cohn SL, Pearson AD, London WB et al (2009) The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. J Clin Oncol 27:289-297
30. Tomioka N, Oba S, Ohira M et al (2008) Novel risk stratification of patients with neuroblastoma by genomic signature which is independent of molecular signature. Oncogene 27:441-449
31. Ando K, Ohira M, Ozaki T et al (2008) Expression of TSLC1, a candidate tumor suppressor gene mapped to chromosome 11q23, is downregulated in unfavorable neuroblastoma without promoter hypermethylation. Int J Cancer 123:2087-2094
32. Ochiai H, Takenobu H, Nakagawa A et al (2010) Bmi1 is a MYCN target gene and regulates tumorigenesis via repression of KIF1Bb and TSLC1 in neuroblastoma. Oncogene 29:2681-2690
33. Kogner P, Barbany G, Dominici C et al (1993) Coexpression of messenger RNA for TRK protooncogene and low affinity nerve growth factor receptor in neuroblastoma with favorable prognosis. Cancer Res 53:2044-2050
34. Nakagawara A, Arima-Nakagawara M, Scavarda NJ et al (1993) Association between high levels of expression of the TRK gene and favorable outcome in human neuroblastoma. N Engl J Med 328:847-854
35. Nakagawara A, Azar CG, Scavarda NJ et al (1994) Expression and function of TRK-B and BDNF in human neuroblastomas. Mol Cell Biol 14:759-767
36. Eggert A, Grotzer MA, Zuzak TJ et al (2001) Resistance to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in neuroblastoma cells correlates with a loss of caspase-8 expression. Cancer Res 61:1314-1319
37. Teitz T, Wei T, Valentine MB et al (2000) Caspase 8 is deleted or silenced preferentially in childhood neuroblastomas with amplification of MYCN. Nat Med 6:529-535
38. Ejeskar K, Aburatani H, Abrahamsson J et al (1998) Loss of heterozygosity of 3p markers in neuroblastoma tumours implicate a tumour-suppressor locus distal to the FHIT gene. Br J Cancer 77:1787-1791
39. Astuti D, Agathanggelou A, Honorio S et al (2001) RASSF1A promoter region CpG island hypermethylation in phaeochromo-cytomas and neuroblastoma tumours. Oncogene 20:7573-7577
40. Mosse YP, Laudenslager M, Khazi D et al (2004) Germline PHOX2B mutation in hereditary neuroblastoma. Am J Hum Genet 75:727-730
41. Trochet D, Bourdeaut F, Janoueix-Lerosey I et al (2004) Germ-line mutations of the paired-like homeobox 2B (PHOX2B) gene in neuroblastoma. Am J Hum Genet 74:761-764
42. Mossé YP, Laudenslager M, Longo L et al (2008) Identification of ALK as a major familial neuroblastoma predisposition gene. Nature 455:930-935
43. Janoueix-Lerosey I, Lequin D, Brugières L et al (2008) Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma. Nature 455:967-970
44. George RE, Sanda T, Hanna M et al (2008) Activating mutations in ALK provide a therapeutic target in neuroblastoma. Nature 455:975-978
45. Chen Y, Takita J, Choi YL et al (2008) Oncogenic mutations of ALK kinase in neuroblastoma. Nature 455:971-974
46. Look AT, Hayes FA, Shuster JJ et al (1991) Clinical relevance of tumor cell ploidy and N-myc gene amplification in childhood neuroblastoma: a Pediatric Oncology Group study. J Clin Oncol 9:581-591
47. Walton JD, Kattan DR, Thomas SK et al (2004) Characteristics of stem cells from human neuroblastoma cell lines and in tumors. Neoplasia 6:645-838
48. Hansford LM, McKee AE, Zhang L et al (2007) Neuroblastoma cells isolated from bone marrow metastases contain a naturally enriched tumor-initiating cell. Cancer Res 67:11234-11243
49. Smith KM, Datti A, Fujitani M et al (2010) Selective targeting of neuroblastoma tumour-initiating cells by compounds identified in stemcell-basedsmallmoleculescreens.EMBOMolMed2:371-384
50. Grinshtein N, Datti A, Fujitani M et al (2011) Small molecule kinase inhibitor screen identifies polo-like kinase 1 as a target for neuroblastoma tumor-initiating cells. Cancer Res 71:1385-1395
51. Corbeil D, Fargeas CA, Huttner WB (2001) Rat prominin, like its mouse and human orthologues, is a pentaspan membrane glyco-protein. Biochem Biophys Res Commun 285:939-944
52. O'Brien CA, Kreso A, Jamieson CHM (2010) Cancer stem cells and self-renewal. Clin Cancer Res 16:3113-3120
53. Takenobu H, Shimozato O, Nakamura T et al (2011) CD133 suppresses neuroblastoma cell differentiation via signal pathway modification. Oncogene 30:97-105
54. Mahller YY, Williams JP, Baird WH et al (2009) Neuroblastoma cell lines contain pluripotent tumor initiating cells that are susceptible to a targeted oncolytic virus. PLoS ONE 4:e4235
55. Shmelkov SV, Jun L, St Clair R et al (2004) Alternative promoters regulate transcription of the gene that encodes stem cell surface protein AC133. Blood 103:2055-2061
56. Schiapparelli P, Enguita-Germán M, Balbuena J et al (2010) Analysis of stemness gene expression and CD133 abnormal methylation in neuroblastoma cell lines. Oncol Rep 24:1355-1362
57. Baba T, Convery PA, Matsumura N et al (2009) Epigenetic regulation of CD133 and tumorigenicity of CD133? ovarian cancer cells. Oncogene 28:209-218
58. Yi JM, Tsai HC, Glöckner SC et al (2008) Abnormal DNA methylation of CD133 in colorectal and glioblastoma tumors. Cancer Res 68:8094-8103